CollPlant Biotechnologies Ltd.

CLGN

IL0004960188

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 21:30:00 23/05/2024 BST			5-day change	1st Jan Change
6.224 ^USD	+4.10%		-2.75%	-2.60%

04-04	CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-02	CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants	CI

CollPlant Holdings Ltd will Change its Name to CollPlant Biotechnologies Ltd

June 21, 2019 at 05:00 am

Effective June 21, 2019, CollPlant Holdings Ltd will change its name to CollPlant Biotechnologies Ltd.

Latest news about CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants	01-02	CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $43,000	11-29	MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
CollPlant Biotechnologies Issued US Patent for Photocurable Dermal Filler	11-01	MT
Wall Street Set to Open Slightly Higher; Weekly Jobless Claims Fall to Near Historic Lows	19/10/23	MT
Top Premarket Decliners	19/10/23	MT
Earnings Flash (CLGN) COLLPLANT Reports Q2 Revenue $10.2M	24/08/23	MT
Earnings Flash (CLGN) COLLPLANT Posts Q2 EPS $0.52	24/08/23	MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
CollPlant to Receive $10 Million Milestone Payment From AbbVie Under Dermal Filler Product Deal; Shares Rise	26/06/23	MT
CollPlant Biotechnologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/05/23	CI
Stratasys, CollPlant Biotechnologies to Bio-Fabricate Human Tissues, Organs	04/04/23	MT
Stratasys Ltd. and Collplant Biotechnologies Ltd. to Transform Healthcare with Industrial-Scale Bioprinting of Tissues and Organs	04/04/23	CI
HC Wainwright Adjusts Price Target on CollPlant Holdings to $11 From $26, Maintains Buy Rating	30/03/23	MT
CollPlant Announces Successful Pre-Clinical Results in 3D Bioprinted Regenerative Breast Implants Porcine Study and Full Achievement of Objectives	04/01/23	CI
Collplant Enriches Portfolio of Rhcollagen-Based Bioinks with Launch of Collink.3Dtm 50L in Powder Form	03/01/23	CI
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	01/12/22	CI
CollPlant Biotechnologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	01/12/22	CI
Earnings Flash (CLGN) COLLPLANT Posts Q3 Revenue $109,000	01/12/22	MT
Earnings Flash (CLGN) COLLPLANT Posts Q3 Loss $-0.34	01/12/22	MT
CollPlant, Tel Aviv University, Sheba Medical Center to Co-Develop Tissue Model for Drug Discovery to Treat Ulcerative Colitis	15/11/22	MT
Collplant Enters into A License and Research Agreement to Co-Develop A “Gut-On-A-Chip” Tissue Model for Drug Discovery and High Throughput Screening of Drugs	15/11/22	CI
CollPlant Biotechnologies Ltd., Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis	15/11/22	CI
Collplant Expands Rhcollagen-Based Bioink Platform with Launch of Collink.3D 90	07/11/22	CI

Chart CollPlant Biotechnologies Ltd.

Duration

Period

More charts

CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).

Sector

Biotechnology & Medical Research

Calendar

28/05/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for CollPlant Biotechnologies Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.224 USD

Average target price

11 USD

Spread / Average Target

+76.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Medical Devices

	1st Jan change	Capi.
COLLPLANT BIOTECHNOLOGIES LTD.	-2.60%	71.28M
MIMEDX GROUP, INC.	-10.66%	1.15B
NIBEC CO., LTD.	-22.77%	125M
KIM FOREST ENTERPRISE CO., LTD.	+1.63%	58.22M
BONUS BIOGROUP LTD.	-1.80%	52.14M

Bio Medical Devices

CollPlant Biotechnologies Ltd.

Equities

CLGN

IL0004960188

Biotechnology & Medical Research

CollPlant Holdings Ltd will Change its Name to CollPlant Biotechnologies Ltd

Latest news about CollPlant Biotechnologies Ltd.

Chart CollPlant Biotechnologies Ltd.

Company Profile

Income Statement Evolution

Ratings for CollPlant Biotechnologies Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Medical Devices